TY  - JOUR
AU  - Remde, H.
AU  - Schmidt-Pennington, L.
AU  - Reuter, M.
AU  - Landwehr, L-S
AU  - Jensen, M.
AU  - Lahner, H.
AU  - Kimpel, O.
AU  - Altieri, B.
AU  - Laubner, K.
AU  - Schreiner, J.
AU  - Bojunga, J.
AU  - Kircher, S.
AU  - Kunze, C. A.
AU  - Pohrt, A.
AU  - Teleanu, Maria-Veronica
AU  - Hübschmann, Daniel
AU  - Stenzinger, A.
AU  - Glimm, Hanno
AU  - Fröhling, Stefan
AU  - Fassnacht, M.
AU  - Mai, K.
AU  - Kroiss, M.
TI  - Outcome of Immunotherapy in Adrenocortical Carcinoma - A retrospective cohort study.
JO  - European journal of endocrinology
VL  - 188
IS  - 6
SN  - 0001-5598
CY  - Bristol
PB  - BioScientifica Ltd.
M1  - DKFZ-2023-01083
SP  - 485-493
PY  - 2023
N1  - 2023 Jun 7;188(6):485-493
AB  - Clinical trials with immune checkpoint inhibitors (ICI) in adrenocortical carcinoma (ACC) have yielded contradictory results. We aimed to evaluate treatment response and safety of ICI in ACC in a real-life setting.Retrospective cohort study of 54 patients with advanced ACC receiving ICI as compassionate use at six German reference centres between 2016 and 2022.Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAE) were assessed.In 52 patients surviving at least 4 weeks after initiation of ICI, ORR was 13.5
KW  - PD-L1 (Other)
KW  - adverse drug reaction (Other)
KW  - immune checkpoint inhibitor (Other)
KW  - mitotane (Other)
KW  - treatment (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37260092
DO  - DOI:10.1093/ejendo/lvad054
UR  - https://inrepo02.dkfz.de/record/276386
ER  -